

## DRAFT Medical Coverage Policy | Hydrogel Spacer Use During Radiotherapy for Prostate Cancer



**EFFECTIVE DATE:** 09|01|2023

**POLICY LAST UPDATED:** 05|17|2023

### OVERVIEW

For low- or intermediate-risk prostate cancer, radiation therapy is an option. Because the rectum lies in close proximity to the prostate, the risk of rectal toxicity is high. One approach is to push the rectum away from the prostate, increasing the space between the 2 and reducing the radiation dose to the rectum. A variety of biomaterials, including polyethylene glycol hydrogels (eg, SpaceOAR™ System) have been evaluated as perirectal spacers.

### MEDICAL CRITERIA

#### Medicare Advantage Plans

Not applicable

#### Commercial Products

Hydrogel spacer use during radiotherapy for prostate cancer may be considered medically necessary when ALL of the following are met:

- Prostate cancer considered low or favorable intermediate risk or clinical stage T1-T2; AND
- Tumor is confined to prostate; AND
- Gleason score  $\leq 7$ ; AND
- Prostate volume  $\leq 80$  cm<sup>3</sup>; AND
- No active bleeding disorder.

### PRIOR AUTHORIZATION

#### Medicare Advantage Plans

Not applicable

#### Commercial Products

Prior authorization is recommended for Commercial Products.

### POLICY STATEMENT

#### Medicare Advantage Plans

Polyethylene-glycol (PEG) hydrogel is covered in patients with clinically localized prostate cancer.

**Note:** Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all Medicare Advantage Plans policies. Therefore, Medicare Advantage Plans policies may differ from Commercial products. In some instances, benefits for Medicare Advantage Plans may be greater than what is allowed by CMS.

#### Commercial Products

Hydrogel spacer use during radiotherapy for prostate cancer may be considered medically necessary when the criteria above are met.

### COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable surgery or not medically necessary benefits/coverage.

## BACKGROUND

### Diagnosis

Prostate cancer is a complex, heterogeneous disease, ranging from microscopic tumors unlikely to be life-threatening to aggressive tumors that can metastasize, leading to morbidity or death. It is the second most common cancer in men, with over 1 in 10 men diagnosed with prostate cancer over their lifetime. Cancer is typically suspected due to increased levels of prostate-specific antigen upon screening. A digital rectal exam may detect nodules, induration, or asymmetry, which is then followed by an ultrasound-guided biopsy with an evaluation of the number and grade of positive biopsy cores.

The Gleason score is calculated by adding together the two grades of cancer cells that make up the largest areas of the biopsied tissue sample. The Gleason score usually ranges from 6 to 10. The lower the Gleason score, the more the cancer cells look like normal cells and are likely to grow and spread slowly.

In intermediate-risk prostate cancer the tumor is confined to the prostate with a prostate-specific antigen (PSA) between 10 and 20, and Gleason score of 7.

Low-risk prostate cancer may be defined by a Gleason score of 6 or less, PSA less than 10 mg/ml, and a tumor that is either non-palpable or only palpable in less than half of one lobe of the prostate.

Clinical staging is based on the digital rectal exam and biopsy results. T1 lesions are not palpable while T2 lesions are palpable but appear to be confined to the prostate. T3 lesions extend through the prostatic capsule, and T4 lesions are fixed to or invade adjacent structures. The most widely used grading scheme for a prostate biopsy is the Gleason system. It is an architectural grading system ranging from 1 (well-differentiated) to 5 (poorly differentiated); the score is the sum of the primary and secondary patterns. A Gleason score of 6 or less is low-grade prostate cancer that usually grows slowly; 7 is an intermediate grade; 8 to 10 is high-grade cancer that grows more quickly. A revised prostate cancer grading system has been adopted by the National Cancer Institute and the World Health Organization shown below.

Grade Group	Gleason Score (Primary and Secondary Pattern)	Cells
1	6 or less	Well differentiated (low grade)
2	7 (3 + 4)	Moderately differentiated (moderate grade)
3	7 (4 + 3)	Poorly differentiated (high grade)
4	8	Undifferentiated (high grade)
5	9-10	Undifferentiated (high grade)

### Treatment

Early localized disease can usually be treated with surgery and radiotherapy, although active surveillance may be adopted in men whose cancer is unlikely to cause major health problems during their lifespan or for whom the treatment might be dangerous. In patients with inoperable or metastatic disease, treatment consists of hormonal therapy and possibly chemotherapy. Treatment decisions are based on the anatomic extent of the lesion, the histologic grade from biopsy, and serum prostate-specific antigen level. Other factors in treatment decisions are expected outcomes, potential complications, along with medical condition, age, comorbidities, and personal preferences. For patients with clinically localized low-risk cancer (no palpable tumor and prostate-specific antigen of ten or less), active surveillance is an option. Definitive therapy with radical prostatectomy or radiation therapy (RT) with external beam and/or brachytherapy is also an option for low

or intermediate risk disease. Dose escalation of RT improves cancer outcomes but also increases the risk of urinary or bowel toxicity. Image-guided RT and intensity-modulated RT may be used to limit margins and reduce toxicity but because the rectum lies in close proximity to the prostate, the risk of rectal toxicity remains high. Hypofractionation, dose escalation, and salvage RT protocols can be particularly prone to rectal toxicity.

### **Hydrogel Perirectal Spacer**

Early localized prostate cancer can usually be treated with surgery and radiotherapy, although active surveillance may be adopted in men whose cancer is unlikely to cause major health problems during their lifespan or for whom the treatment might be dangerous. In patients with inoperable or metastatic disease, treatment consists of hormonal therapy and possibly chemotherapy. Treatment decisions are based on the anatomic extent of the lesion, the histologic grade from biopsy, and serum prostate-specific antigen level. Other factors in treatment decisions are expected outcomes, potential complications, other medical conditions, age, and comorbidities, and personal preferences. For patients with clinically localized low-risk cancer (no palpable tumor and prostate-specific antigen of 10 or less), active surveillance is an option. Definitive therapy with radical prostatectomy or radiation therapy (RT) with external beam and/or brachytherapy is also an option for low- or intermediate-risk disease. Dose escalation of RT improves cancer outcomes but also increases the risk of urinary or rectal toxicity. Image-guided RT and intensity-modulated RT may be used to limit margins and reduce toxicity, but because the rectum lies in close proximity to the prostate, the risk of rectal toxicity remains high. Hypofractionation that reduces the number of treatments, dose-escalation, and salvage RT protocols can be particularly prone to rectal toxicity. One approach to the problem of rectal toxicity is to push the rectum away from the prostate, increasing the space between the 2organs and reducing the radiation dose to the anterior rectal wall. A variety of biomaterials, including collagen, polyethylene glycol (PEG) hydrogels, and absorbable balloons have been evaluated as a means to reduce rectal radiation exposure. The SpaceOAR System is the first PEG hydrogel that was cleared by the U.S. Food and Drug Administration (FDA) specifically for use during RT of the prostate.

### **Medicare Advantage Products**

#### **Summary of Evidence**

Some of the literature endorses that the injection of the PEG spacer is usually safe and without untoward events once the physician becomes familiar with the procedure. Other references not cited here have described materials used to increase the distance between the prostate and rectum during radiation therapy for prostate cancer. Hyaluronic acid, human collagen, interstitial balloons, as well as synthetic polyethylene glycols have been used.

Reducing rectal radiation exposure during prostate cancer radiotherapy is desirable. The PEG spacer can be considered selectively when state-of-the-art localization techniques do not suffice to either improve oncologic cure rates or reduce side effects.

### **CODING**

#### **Medicare Advantage Plans and Commercial Products**

The following CPT code(s) is covered for Medicare Advantage Plans and considered medically necessary for Commercial Products when the criteria above has been met:

**55874** Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed

### **RELATED POLICIES**

Medicare Advantage Plans National and Local Coverage Determinations

### **PUBLISHED**

Provider Update, July 2023

Provider Update, September 2022

Provider Update, March 2021  
Provider Update, April 2020  
Provider Update, May 2019

## REFERENCES

1. Gleason DF. Classification of prostatic carcinomas. *Cancer Chemother Rep.* Mar 1966; 50(3): 125-8. PMID 5948714
2. SEER Database. <https://seer.cancer.gov/seerinqury/index.php?page=view&id=20170036&type=q>. Accessed June 24,2022.
3. Forero DF, Almeida N, Dendukuri N. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a healthtechnology assessment. Report No. 82. April 16, 2018. <https://muhc.ca/sites/default/files/micro/m-TAU/SpaceOAR.pdf>. Accessed June 23, 2022.
4. Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. *Urology.* Jan 2015; 85(1): 101-5. PMID 25530370
5. McDonald AM, Baker CB, Popple RA, et al. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy. *Radiat Oncol.* Jun 03 2014; 9: 129. PMID 24893842
6. Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys.* Aug 01 2015; 92(5): 971-977. PMID 26054865
7. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. *Int J Radiat Oncol Biol Phys.* Apr 01 2017; 97(5): 976-985. PMID 28209443
8. Fischer-Valuck BW, Chundury A, Gay H, et al. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. *Pract Radiat Oncol.* May 2017; 7(3): 195-202. PMID 28089528
9. Miller LE, Efstathiou JA, Bhattacharyya SK, et al. Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open.* Jun 01 2020; 3(6): e208221. PMID 32585020
10. Babar M, Katz A, Ciatto M. Dosimetric and clinical outcomes of SpaceOAR in men undergoing external beam radiation therapy for localized prostate cancer: A systematic review. *J Med Imaging Radiat Oncol.* Jun 2021; 65(3): 384-397. PMID 33855816
11. Whalley D, Hruby G, Alfieri F, et al. SpaceOAR Hydrogel in Dose-escalated Prostate Cancer Radiotherapy: Rectal Dosimetry and Late Toxicity. *Clin Oncol (R Coll Radiol).* Oct 2016; 28(10): e148-54. PMID 27298241
12. Te Velde BL, Westhuyzen J, Awad N, et al. Can a peri-rectal hydrogel spaceOAR programme for prostate cancer intensity-modulated radiotherapy be successfully implemented in a regional setting?. *J Med Imaging Radiat Oncol.* Aug 2017; 61(4): 528-533. PMID 28151584
13. Pinkawa M, Piroth MD, Holy R, et al. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis. *Strahlenther Onkol.* Oct 2012; 188(10): 917-25. PMID 22933033
14. Pinkawa M, Berneking V, Konig L, et al. Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. *Strahlenther Onkol.* Jan 2017; 193(1): 22-28. PMID 27632342
15. Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ. Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results. *International journal of radiation oncology, biology, physics.* 2017;99(2):374-377.
16. Te Velde BL, Westhuyzen J, Awad N, et al. Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion. *J Med Imaging Radiat Oncol.* Dec 2019; 63(6): 836-841. PMID 31520465

17. Seymour ZA, Hamstra DA, Daignault-Newton S, et al. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. *BJU Int.* Sep 2020; 126(3): 367-372. PMID 32333714
18. Chao M, Ow D, Ho H, et al. Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel spacer. *J Contemp Brachytherapy.* Feb 2019; 11(1): 8-13. PMID 30911304
19. Kahn J, Dahman B, McLaughlin C, et al. Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation. *Brachytherapy.* Mar 2020; 19(2): 228-233. PMID 32085930
20. Nehlsen AD, Sindhu KK, Moshier E, et al. The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy. *Brachytherapy.* Mar-Apr 2021; 20(2): 296-301. PMID 33199175
21. Butler WM, Kurko BS, Scholl WJ, et al. Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants. *J Contemp Brachytherapy.* Apr 2021; 13(2): 145-151. PMID 33897787
22. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer v4.2022 [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed June 24, 2022.
23. National Institute for Health and Care Excellence. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. IPG590 2017. [/https://www.nice.org.uk/guidance/ipg590](https://www.nice.org.uk/guidance/ipg590). Last Accessed June 23, 2022.
24. Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. *J Urol.* Oct 09 2018. PMID 30316897
25. American College of Radiology. ACR appropriateness criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer. 2016. <https://acsearch.acr.org/docs/69396/Narrative/>. Accessed June 24, 2022.
26. Local Coverage Determination (LCD): Prostate Rectal Spacers (L37485) <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37485&ver=16&bc=0>. Accessed July 15, 2022.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

